These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 28486043)

  • 21. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
    Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
    Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H
    J Hematol Oncol; 2023 Jul; 16(1):73. PubMed ID: 37422688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
    Zeidan AM; Gore SD; Komrokji RS
    Expert Rev Hematol; 2013 Jun; 6(3):251-4. PubMed ID: 23782079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
    Kobayashi Y; Munakata W; Ogura M; Uchida T; Taniwaki M; Kobayashi T; Shimada F; Yonemura M; Matsuoka F; Tajima T; Yakushijin K; Minami H
    Int J Hematol; 2018 Jan; 107(1):83-91. PubMed ID: 28905323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.
    Scott BL; Ramakrishnan A; Storer B; Becker PS; Petersdorf S; Estey EH; Deeg HJ
    Br J Haematol; 2010 Mar; 148(6):944-7. PubMed ID: 20064151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report.
    Todaro J; Bollmann PW; Rother ET; del Giglio A
    Sao Paulo Med J; 2015; 133(3):271-4. PubMed ID: 25250799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
    Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
    Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.
    Almeida AM; Pierdomenico F
    Leuk Res; 2012 Sep; 36(9):e211-3. PubMed ID: 22622173
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
    Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
    Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of azacitidine in chronic myelomonocytic leukemia.
    Costa R; Abdulhaq H; Haq B; Shadduck RK; Latsko J; Zenati M; Atem FD; Rossetti JM; Sahovic EA; Lister J
    Cancer; 2011 Jun; 117(12):2690-6. PubMed ID: 21656746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
    Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
    Usuki K; Ohtake S; Honda S; Matsuda M; Wakita A; Nawa Y; Takase K; Maeda A; Sezaki N; Yokoyama H; Takada S; Hirano D; Tomikawa T; Sumi M; Yano S; Handa H; Ota S; Fujita H; Fujimaki K; Mugitani A; Kojima K; Kajiguchi T; Fujimoto K; Asou N; Usui N; Ishikawa Y; Katsumi A; Matsumura I; Miyazaki Y; Kiyoi H
    Int J Hematol; 2024 Feb; 119(2):130-145. PubMed ID: 38091231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
    Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
    Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
    Sekeres MA; List AF; Cuthbertson D; Paquette R; Ganetzky R; Latham D; Paulic K; Afable M; Saba HI; Loughran TP; Maciejewski JP
    J Clin Oncol; 2010 May; 28(13):2253-8. PubMed ID: 20354132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
    Zhou X; Friedlander S; Kupperman E; Sedarati F; Kuroda S; Hua Z; Yuan Y; Yamamoto Y; Faller DV; Haikawa K; Nakai K; Bowen S; Dai Y; Venkatakrishnan K
    Clin Transl Sci; 2021 May; 14(3):1069-1081. PubMed ID: 33503305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
    Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
    Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
    Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
    Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
    [No Abstract]   [Full Text] [Related]  

  • 38. Eprenetapopt Plus Azacitidine in
    Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
    J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.
    Assouline S; Michaelis LC; Othus M; Hay AE; Walter RB; Jacoby MA; Schroeder MA; Uy GL; Law LY; Cheema F; Sweet KL; Asch AS; Liu JJ; Moseley AB; Maher T; Kingsbury LL; Fang M; Radich J; Little RF; Erba HP
    Leuk Lymphoma; 2023 Feb; 64(2):473-477. PubMed ID: 36517990
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
    Garcia-Manero G; Tambaro FP; Bekele NB; Yang H; Ravandi F; Jabbour E; Borthakur G; Kadia TM; Konopleva MY; Faderl S; Cortes JE; Brandt M; Hu Y; McCue D; Newsome WM; Pierce SR; de Lima M; Kantarjian HM
    J Clin Oncol; 2012 Jun; 30(18):2204-10. PubMed ID: 22585696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.